



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL TRAF4 ASSOCIATED CELL CYCLE PROTEINS,
COMPOSITIONS AND METHODS OF USE

the specification of which

(Check one) ☐ is attached hereto
☒ was filed on September 23, 1999 as
Application Serial No. 09/404,010
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby appoint, for the benefit of and as agent for the Assignee of this application and to my exclusion if there is now or hereafter such an Assignee:

Harold C. Hohbach	17,757	Steven F. Caserza	29,780
Aldo J. Test	18,048	Laura L. Kulhanjian	33,257
Thomas O. Herbert	18,612	Michael A. Kaufman	32,988
Donald N. MacIntosh	20,316	Janet E. Muller	35,294
Edward S. Wright	24,903	Edward N. Bachand	37,085
David J. Brezner	24,774	R. Michael Ananian	35,050
Richard E. Backus	22,701	Stephen M. Knauer	38,208
James A. Sheridan	25,435	Robin M. Silva	38,304
Robert B. Chickering	24,286	David C. Ashby	36,432
Richard F. Trecartin	31,801	Julian Caplan	14,785
Dolly A. Vance	39,054		


attorneys and agents with full power of substitution and revocation to prosecute the above-identified application for Letters Patent and to transact all business in the Patent Office connected therewith, provided that if any one of said attorneys ceases being affiliated with the law firm of Flehr Hohbach Test Albritton & Herbert LLP as partner, employee or of counsel, such attorney's appointment as attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated. .

Direct all telephone calls to Dolly A. Vance at (415) 781-1989.
Address all correspondence to:

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP
Suite 3400, Four Embarcadero Center
San Francisco, California 94111

File No. A-68294/RMS/DAV

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor:	Ying Luo
Inventor's signature:	
Date:	11/24/99
Residence:	32 Chester Circle, Los Altos, CA 94022
Citizenship:	China
Post Office Address:	32 Chester Circle, Los Altos, CA 94022

Full name of second joint
inventor, if any:

Xiang Xu

Inventor's signature:



Date:

NOV. 24, 1997

Residence:

185 Cymbidium Circle
South San Francisco, CA 94080


Citizenship:

China

Post Office Address:

185 Cymbidium Circle
South San Francisco, CA 94080

Applicant or Patentee: Luo, Yal. Attorney's Docket No. A-682/RMS/DAV
Serial or Patent No.: 09/404,010
Filed or Issued: September 23, 1999
For: NOVEL TRAF4 ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE



VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am
☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN: RIGEL PHARMACEUTICALS, INC.
ADDRESS OF SMALL BUSINESS CONCERN: 240 East Grand Avenue, South San Francisco, CA 94080

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled, NOVEL TRAF4 ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE by inventor(s) Ying Luo and Xiang Xu, described in

☐ the specification filed herewith
☒ application serial no. 09/404,010, filed September 23, 1999
☐ patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME: _____
ADDRESS: _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Donald G. Payan
TITLE IN ORGANIZATION Executive Vice President & Chief Scientific Officer
ADDRESS OF PERSON SIGNING 240 East Grand Avenue
South San Francisco, CA 94080
SIGNATURE [Signature] DATE 11/24/99
619705